Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-16-559633
Filing Date
2016-04-27
Accepted
2016-04-27 16:33:36
Documents
11
Effectiveness Date
2016-04-27

Document Format Files

Seq Description Document Type Size
1 DEFA14A d185260ddefa14a.htm DEFA14A 30470
2 GRAPHIC g185260not01a.jpg GRAPHIC 43752
3 GRAPHIC g185260not01b.jpg GRAPHIC 18883
4 GRAPHIC g185260not01c.jpg GRAPHIC 8261
5 GRAPHIC g185260not01d.jpg GRAPHIC 13905
6 GRAPHIC g185260not01e.jpg GRAPHIC 7329
7 GRAPHIC g185260not01f.jpg GRAPHIC 2385
8 GRAPHIC g185260not01g.jpg GRAPHIC 3886
9 GRAPHIC g185260not01h.jpg GRAPHIC 2985
10 GRAPHIC g185260not02anewjpg.jpg GRAPHIC 7728
11 GRAPHIC g185260not02b.jpg GRAPHIC 3886
  Complete submission text file 0001193125-16-559633.txt   188349
Mailing Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020
Business Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 720-940-2200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-22873 | Film No.: 161595809
SIC: 2835 In Vitro & In Vivo Diagnostic Substances